^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
06/26/2020
Excerpt:
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
Secondary therapy:
cytarabine
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
11/21/2018
Excerpt:
DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Secondary therapy:
cytarabine
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
For AML patients declining intensive remission induction therapy...regimens include venetoclax combined with chemotherapy...or glasdegib combined with LDAC.
Secondary therapy:
cytarabine